Eylea 114.3 mg/ml solution for injection

DRUG3 trials

Sponsors

Bayer AG, Alvotech Swiss AG, Medical University Of Graz

Conditions

Diabetic Macular EdemaDiabetic macular edema (DME)Neovascular age-related macular degenerationNeovascular age-related macular degeneration (nAMD)

Phase 3

A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT29 Compared with Eylea High Dose (HD) in Participants with Diabetic Macular Edema (ALVOEYE-HD)

Not yet recruitingCTIS2025-522231-34-00

Alvotech Swiss AGDiabetic Macular Edema

Target: 11Updated: 2026-03-06

Phase 4

(22578) An open-label, non-randomized, multi-center, phase 4 pharmacokinetic study to evaluate the systemic exposure after bilateral intravitreal administration of high dose (8 mg) aflibercept in adults with diabetic macular edema or neovascular age-related macular degeneration

CompletedCTIS2024-511665-11-00

Bayer AGDiabetic macular edema (DME), Neovascular age-related macular degeneration (nAMD)

Start: 2024-08-29End: 2025-10-14Target: 45Updated: 2025-02-25

Two initial aflibercept 8 mg loading doses in treatment-naive neovascular AMD

Not yet recruitingCTIS2025-523478-17-00

Medical University Of GrazNeovascular age-related macular degeneration

Target: 50Updated: 2026-02-16